Select a category

New York Registry Shares of ASML Holding (ASML) plunged Tuesday after the company accidentally released its third-quarter results a day earlier than expected.

"Due to a technical error, information relating to our Q3 2024 results was erroneously published earlier today on part of our website asml.com," the company said. "For transparency, ASML brought forward publication of its full Q3 2024 results to October 15th."

The Dutch semiconductor-gear manufacturer now expects 2025 net sales to land between 30 billion euros and 35 billion euros ($33.1 billion to $38.6 billion). That's within the lower half of the company's previously projected range and below the 36.10-billion-euro consensus estimate of analysts compiled by Visible Alpha. 

For the third quarter, net sales were above estimates at 7.47 billion euros, but net bookings of 2.63 billion euros fell well short of the expected 5.59 billion euros.

"While there continue to be strong developments and upside potential in AI, other market segments are taking longer to recover. It now appears the recovery is more gradual than previously expected," Chief Executive Officer (CEO) Christophe Fouquet said. "This is expected to continue in 2025, which is leading to customer cautiousness."

ASML shares tumbled 17% intraday Tuesday, bringing them into negative territory for the year.

Read more on Investopedia

Nvidia (NVDA) shares fell from yesterday's all-time closing high, and shares of other chipmakers declined, following indications the Biden administration is considering limiting the export of artificial intelligence chips to some countries in the Middle East.

reported that White House officials have discussed putting a cap on export licenses to certain nations because of national security concerns. The focus was on Persian Gulf countries that have a growing interest in AI and the funding to purchase those technologies, the report said, adding that the discussions are in the early stages.

Also weighing on semiconductor stocks was a warning from chipmaker equipment ASML Holding (ASML), which released its third quarter earnings a day earlier than expected.

"While there continue to be strong developments and upside potential in AI, other market segments are taking longer to recover," said CEO Christophe Fouquet. "It now appears the recovery is more gradual than previously expected.” 

ASML predicted 2025 sales of EUR30 billion to EUR35 billion ($32.7 billion to $38.1 billion), which is in the lower half of the range of its previous guidance.

New York-traded shares of ASML sank some 16%, pulling them into the red for the year. The PHLX index of semiconductor stocks fell more than 4%. Nvidia's shares were down nearly 5%, though they remain up more than 160% in 2024.

Read more on Investopedia

Charles Schwab (SCHW) shares soared Tuesday as the financial services company reported better third-quarter results than analysts had expected, and also lifted its projections for full-year revenue.

The investment management firm reported $4.85 billion in total revenue, up about 5% from the same time last year and higher than analysts had expected, per estimates compiled by Visible Alpha. Profits were also higher than expected, and jumped 25% to $1.41 billion, while net interest income (NII) fell by a few million to $2.22 billion, narrowly above estimates.

The company also lifted its revenue projection for the full year, calling for a 2% to 3% increase, up from previous estimates of flat to up 2%.

CFO Mike Verdeschi said in Tuesday's earnings call that the update was due to "a higher starting balance for transactional cash balances and reduced supplemental funding balances at the bank."

"We anticipate coming into 2025 with good momentum and expect it to further build in the year ahead," Verdeschi said, noting that the "usual considerations" of potential changes like macroeconomic factors and interest rates could impact Schwab's performance.

Charles Schwab shares were up about 7% early Tuesday afternoon, trading at their highest level in three months. The stock is now back into positive territory for the year.

The stock plunged in mid-July following the firm's second-quarter report, when CEO Walt Bettinger said it planned to reduce the size of its bank to improve profitability.

Read more on Investopedia

Shares of UnitedHealth Group (UNH) tumbled Tuesday after the company lowered its full-year profit outlook to reflect the impact of a cyberattack against its Change Healthcare division in February.

The health insurer dropped its earnings per share (EPS) forecast to between $15.50 and $15.75 from $15.95 to $16.40. On an adjusted basis, the company said it has absorbed an estimated 75 cents per share of disruption from the cyberattack, 10 cents more than its prior-quarter estimate. 

In February, the company announced that Change Healthcare’s information technology systems had been hit with "a suspected nation-state associated cyber security threat" that disrupted medical billing and care authorization portals.

Shares of the company fell more than 9% at the opening bell Tuesday—enough that the stock is pulling the Dow Jones Industrial Average into the red nearly by itself. The average is down despite only a third of its 30 components trading lower, with next-biggest decliner, Intel (INTC), down just 2%. Recently, UnitedHealth shares were 7% lower at $561.16.

In the third quarter, UnitedHealth's revenue grew 9% year-over-year to $100.8 billion, beating the Street's analyst consensus from Visible Alpha. Net income was $6.1 billion, $6.51 per share, which missed expectations.

The company attributed its revenue growth to “strong expansion in people served at Optum and UnitedHealthcare.” Optum revenue rose more than 12% year-over-year to $63.9 billion, just above expectations.

Optum, a subsidiary of UnitedHealth, includes a mail-order pharmacy division, a health savings accounts (HSA) arm and a health-care provider payment processing operation.

Read more on Investopedia

Shares of Wolfspeed (WOLF) soared nearly 25% Tuesday when the maker of high-speed semiconductors reported it could receive as much as $2.5 billion in funding under the CHIPS and Science Act of 2022, and from an investment group.

The company noted that the U.S. Department of Commerce has proposed $750 million in direct funding from the CHIPS Act, and that it expects $1.0 billion in refunds from the tax credit included in the legislation. 

It also announced that a consortium of investment funds led by Apollo, The Baupost Group, Fidelity Management & Research Company, and Capital Group agreed to provide an additional $750 million.

Wolfspeed explained that it would use the money to expand domestic manufacturing of chips with its silicon carbide technology, which the company calls "a superior alternative to silicon" for high-power applications, including "EV powertrains, e-mobility, renewable energy systems, battery energy storage systems, and AI and cryptocurrency data centers."

Commerce Secretary Gina Raimondo said federal investment in firms like Wolfspeed are "a meaningful step towards reigniting U.S. manufacturing of the chips" behind technologies such as AI, EVs, and clean energy.

Apollo Partner Joseph Jackson added that the firm believes "Wolfspeed is at the forefront of a critical transformation in sustainable transportation and ensuring that the company has durable capital access to complete its expansion plans will help solidify its leadership in this space."

Even with today's jump, Wolfspeed shares have lost two-thirds of their value this year. 

Read more on Investopedia

Johnson & Johnson (JNJ) shares advanced Tuesday after the pharmaceutical and medical device company posted better third-quarter sales and adjusted profit than expected.

Johnson & Johnson reported $22.47 billion in revenue, up 5% year-over-year and better than analysts had projected, according to estimates compiled by Visible Alpha. It registered $2.69 billion in net income, down 38% and well short of expectation, on billions in one-time expenses like legal costs and acquisitions.

After accounting for over $3 billion in one-time expenses like legal costs, "intangible asset amortization expense," and the cost of acquisitions, Johnson & Johnson's adjusted profit of $5.88 billion came in more than half a billion dollars higher than expected.

The company also adjusted its full-year outlook, lifting sales projections to $88.4 billion to $88.8 billion from the prior range of $88 billion to $88.4 billion. Still, Johnson & Johnson lowered its adjusted earnings per share (EPS) projections to $9.88 per share to $9.98 per share from $9.97 to $10.07 to account for the impact of its recently completed acquisition of V-Wave, which develops treatments for heart failure.

Chief Executive Officer (CEO) Joaquin Duato said the company's recent drug approvals and development milestones of other projects is "further strengthening our confidence in our near- and long-term growth targets."

Johnson & Johnson shares fell in premarket trading after the report but were up 2% in late-morning trading. They are about 5% higher this year.

—This story has been updated with the latest share price information.

Read more on Investopedia